Published in Medical Letter on the CDC and FDA, September 11th, 2005
The company reported total revenue increases of 28% from the second quarter of 2004 and sales of manufactured products increase of 77% compared to the same period last year.
The company received U.S. Food and Drug Administration (FDA) 510(k) clearance to market MiniLoc, during the quarter.
Revenues for the second quarter of 2005 were $1.7 million, an increase of 28% from the $1.3 million recorded in the same period last year. Net loss for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.